EDITORIAL ARTICLE
Immunobiological aspects of rheumatoid arthritis
More details
Hide details
Online publication date: 2011-08-30
Reumatologia 2011;49(4):223-230
KEYWORDS
ABSTRACT
Great number of molecular structures operating in rheumatoid arthritis (RA) present the evolutionary events in biology. Genesis of RA is closely linked to susceptibility genes and environmentals factors. The latter are modifying agents of genotype and signals initiating the disease. Inflammation exhibits very complex system in term of cooperation between cells – genes – molecules. The signal transduction cascade is followed by “unformed biological state” (Fig. 1). The crossing of border line in terms of homeostasis produces complex inflammatory events. The natural defense mechanisms are ineffective in protecting us from the disease. Modifying drugs, including biological agents, suppress the hyperactivity of cells, blocking “immunologic irritation”.
REFERENCES (18)
1.
Ostanek M, Ciechanowicz H. Czynniki genetyczne w patogenezie reumatoidalnego zapalenia stawów. Reumatologia 2009; 47: 143-150. .
2.
Paradowska-Gorycka A, Wojtecka-Łukasik E, Trefler J, et al. Association between IL-17F gene polymorphisms and suseptibility to and severity of rheumatoid arthritis (RA). Scand J Immunol 2010; 72: 134-141. .
3.
Toonen EJ, Barrera P, Radstake TR, et al. Gene expression in rheumatoid arthritis: current concepts and future directions. Ann Rheum Dis 2008; 67: 1663-1669. .
4.
Crispín JC, Kyttaris V, Juang YT, Tsokos GC. Systemic lupus erythematosus – new molecular targets. Ann Rheum Dis 2007; 66: 65-69. .
5.
van der Maarel SM. Epigenetic mechanisms in health and disease. Ann Rheum Dis 2008; 67 Suppl 3: 97-100. .
6.
Mackiewicz S. Reumatoidalne zapalenie stawów: koncepcje patogenetyczne i terapeutyczne. Monografia konferencji reumatologicznej. Poznań 1997; 1: 5-40. .
7.
Szmyrka-Kaczmarek M, Wiland P. Tocilizumab – inhibitor receptora interleukiny 6 – nowa opcja terapeutyczna w leczeniu reumatoidalnego zapalenia stawów. Reumatologia 2009; 47: 85-94. .
8.
Paradowska-Gorycka A, Maśliński S. Komórki Th17 w patogenezie reumatoidalnego zapalenia stawów. Reumatologia 2010; 48: 337-344. .
9.
Mackiewicz S. Geneza reumatoidalnego zapalenia stawów a możliwości terapii. Reumatologia 2010; 48: 11-13. .
10.
Adler G. Cytokiny w początkowych etapach odpowiedzi odpornościowej. Reumatologia 2009; 47: 230-235. .
11.
Paradowska-Gorycka A, Grzybowska-Kowalczyk A, Wojtecka-Łukasik E, Maśliński S. IL-23 in the pathogenesis of rheumatoid arthritis. Scand J Immunol 2010; 71: 134-145. .
12.
Feldmann M, Maini RN. Anti-TNF therapy of rheumatoid arthritis. Ann Rev Immunol 2001; 16: 163-196. .
13.
Smolen J, Steiner M. Therapeutic strategies for rheumatoid arthritis. Nature Rev 2003; 2: 473-488. .
14.
Li L, Chen XP, Li YJ. MicroRNA-146a and human disease. Scand J Immunol 2010; 71: 227-231. .
15.
Sioud M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol 2011; 73: 79-84. .
16.
Vasilopoulos Y, Gkretsi V, Armaka M, et al. Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis. Ann Rheum Dis 2007; 66 Suppl 3: 23-28. .
17.
Mackiewicz S. Racjonalne podstawy terapii modyfikującej. Reumatologia 2010; 48: 289-292. .
18.
Mackiewicz S. Glukokortykoidy: mity i fakty. Reumatologia 2007; 45: 198-204.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.